Boxer Capital Management LLC Takes Position in Zura Bio Limited (NASDAQ:ZURA)

Boxer Capital Management LLC purchased a new stake in Zura Bio Limited (NASDAQ:ZURA - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 300,000 shares of the company's stock, valued at approximately $750,000. Boxer Capital Management LLC owned approximately 0.46% of Zura Bio at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in ZURA. State Street Corp boosted its position in Zura Bio by 47.5% in the third quarter. State Street Corp now owns 395,059 shares of the company's stock valued at $1,604,000 after buying an additional 127,300 shares in the last quarter. Barclays PLC boosted its holdings in shares of Zura Bio by 777.1% during the 3rd quarter. Barclays PLC now owns 64,061 shares of the company's stock valued at $260,000 after acquiring an additional 56,757 shares in the last quarter. Geode Capital Management LLC increased its holdings in Zura Bio by 70.6% in the 3rd quarter. Geode Capital Management LLC now owns 912,625 shares of the company's stock worth $3,706,000 after purchasing an additional 377,545 shares in the last quarter. SG Americas Securities LLC increased its holdings in Zura Bio by 51.6% in the 4th quarter. SG Americas Securities LLC now owns 23,005 shares of the company's stock worth $58,000 after purchasing an additional 7,828 shares in the last quarter. Finally, Rhumbline Advisers raised its position in Zura Bio by 37.3% in the fourth quarter. Rhumbline Advisers now owns 37,657 shares of the company's stock valued at $94,000 after purchasing an additional 10,231 shares during the last quarter. 61.14% of the stock is owned by institutional investors.

Zura Bio Stock Down 0.8 %

Zura Bio stock traded down $0.01 during trading hours on Wednesday, reaching $1.21. 227,645 shares of the company's stock were exchanged, compared to its average volume of 388,671. The firm's 50 day simple moving average is $1.28 and its 200 day simple moving average is $2.17. Zura Bio Limited has a twelve month low of $0.97 and a twelve month high of $6.35. The firm has a market capitalization of $82.73 million, a PE ratio of -2.25 and a beta of 0.05.

Zura Bio (NASDAQ:ZURA - Get Free Report) last issued its earnings results on Tuesday, March 25th. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.09. The business had revenue of $0.00 million during the quarter. Analysts anticipate that Zura Bio Limited will post -0.65 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on ZURA shares. Oppenheimer reaffirmed an "outperform" rating and issued a $19.00 price objective (down previously from $20.00) on shares of Zura Bio in a research note on Wednesday, March 26th. Chardan Capital decreased their price target on shares of Zura Bio from $12.00 to $10.00 and set a "buy" rating for the company in a research report on Wednesday, March 26th. HC Wainwright reissued a "buy" rating on shares of Zura Bio in a research note on Thursday, April 3rd. Finally, Guggenheim restated a "buy" rating and issued a $15.00 price objective on shares of Zura Bio in a report on Wednesday, March 26th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of $14.67.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.